Shared by @Yosukemino2 San in one of his linkedIn post.. go a follow him there as well! (https://www.linkedin.com/in/yosuke-mino-310139212/)
September 20, 2026
The Japanese Society of Generic and Biosimilar Medicines (General Incorporated Association)
Recommendations for the Management and Operation of Nitrosamines in Active Pharmaceutical Ingredients (APIs)
Pharmaceutical Policy Subcommittee: Nobuya Koyama
API Subcommittee: Masaki Muto
In July 2018, N-nitrosodimethylamine (hereinafter, NDMA) and N-nitrosodiethylamine (hereinafter, NDEA), which are considered carcinogenic to humans, were detected in valsartan active pharmaceutical ingredients (APIs) manufactured at a facility in China, leading to global recalls—including in Japan—of valsartan drug products using this API. Following this incident, nitrosamines such as NDMA were also detected in Japan in peptic ulcer treatments like ranitidine and nizatidine, as well as the diabetes treatment metformin, resulting in voluntary recalls of certain products. Subsequently, Nitrosamine Drug Substance-Related Impurities (NDSRIs), in which the amine moiety constituting the API is directly nitrosated, became a matter of concern. In 2024, N-nitrosomirabegron derived from the active ingredient was detected in the overactive bladder treatment mirabegron; NDEA was detected due to degradation during storage in the Parkinson’s disease treatment entacapone; and N-nitrosocinacalcet, presumed to result from a reaction with nitrites in excipients, was detected in the hyperparathyroidism treatment cinacalcet. In the most recent large-scale incident, investigations of APIs and drug products by domestic manufacturers of the ADHD treatment atomoxetine confirmed the presence of N-nitrosoatomoxetine in some products, leading multiple companies to announce voluntary recalls.
On the other hand, for impurities such as NTTP (abbreviation) in the type 2 diabetes treatment sitagliptin and N-nitrosonortriptyline in the tricyclic antidepressant nortriptyline, companies conducted scientific and medical risk assessments, resulting in some products implementing improvement measures in parallel with continued supply rather than undergoing voluntary recalls.
Currently, the management of nitrosamines is operated in various countries in compliance with the ICH-M7 guideline; however, we believe that without a certain degree of operational flexibility, supply risks will increase excessively, potentially leading to drug shortages.
Therefore, the Pharmaceutical Policy Subcommittee and the API Subcommittee of the Japanese Society of Generic and Biosimilar Medicines concluded that clear recommendations regarding the operational management of nitrosamines in APIs are necessary, and have decided to publish them here.
We hope that all relevant parties will review the contents of these recommendations and give them appropriate consideration.
September 20, 2026
The Japanese Society of Generic and Biosimilar Medicines (GEBS Society)
Joint Submission by the Pharmaceutical Policy Subcommittee and the API Subcommittee
Recommendations for the Management and Operation of Nitrosamines in Active Pharmaceutical Ingredients (APIs)
Since its establishment in 2003 (formerly the Japan Generic Medicines Study Group), the Japanese Society of Generic and Biosimilar Medicines has consistently worked from an academic standpoint toward the sound promotion of generic and biosimilar pharmaceuticals in Japan. Leveraging the condition in which the patent period of active ingredients has expired and become available as public assets, providing safe, reliable, and highly usable pharmaceuticals to medical care while keeping drug prices down is also a major expectation of the public.
As of 2026, the usage rate of generic drugs exceeds 80%, and they are used daily to protect the health of the Japanese people as part of the social infrastructure; the need for their stable supply has grown ever stronger and has become a social obligation.
However, starting with the detection of NDMA (N-nitrosodimethylamine) in valsartan APIs in 2018, numerous pharmaceutical recalls related to nitrosamines have occurred both domestically and internationally, severely impacting the stability of the medical supply. In recent years, tightened regulations on nitrosamines have become stricter year by year, resulting in a “de facto zero-risk requirement” at the operational level. Consequently, in addition to increased analytical workloads, difficulties in ensuring the reproducibility of measured values, and sudden non-conformities due to spontaneous formation at the formulation stage, investigations to eliminate nitrosamine formation risks from multifaceted perspectives—such as precursors, reaction conditions, catalysts, and impurity profiles—have drastically increased when establishing synthesis processes for APIs and intermediates, rapidly expanding the burden on R&D and manufacturing departments. Verification work accompanying increased process changes and responses to regulatory authorities have also grown more complex, exposing practical limits even at the synthesis stage.
Furthermore, serious impacts on the entire pharmaceutical supply system are occurring, such as supply stagnation caused by review delays.
These recommendations call for a transition to scientific and realistic regulatory operations after fairly evaluating these practical limitations and the burden on manufacturing sites.
1. Background of the Nitrosamine Issue
(1) What are N-Nitrosamines?
A general term for chemical substances formed by the reaction of amines with nitrites or nitrogen oxides; in the ICH M7 guideline, they are classified as the “Cohort of Concern” and positioned as high-potency genotoxic carcinogens alongside aflatoxin-like and azoxy compounds.
(Chemical reaction diagram showing a secondary amine reacting with $\text{NaNO}_2$ and $\text{H}^+$ to form an N-nitrosamine with an $\text{N-N=O}$ bond)
-
ICH: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
-
ICH M7: Guideline established by ICH for assessing and controlling the carcinogenic risk of mutagenic impurities in pharmaceuticals
(2) The Valsartan Incident
In July 2018, N-nitrosodimethylamine (NDMA), known as a potent genotoxic carcinogen, was detected in valsartan API manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd. (hereinafter, Huahai), an API manufacturing facility in China. In response, European regulatory authorities decided to recall products using the API manufactured by Huahai.
Regarding the cause of NDMA contamination in the valsartan API, it was found that NDMA was formed during the recovery and reuse process of solvents (DMSO, dimethylformamide) in the manufacturing process by reacting with reagents used in the synthesis of the tetrazole ring.
In Japan, upon receiving this information, a voluntary recall was announced by the marketing authorization holder for the drug product using the relevant API (Valsartan Tablets “AA” [ASKA Pharmaceutical]).
It has been pointed out that NDMA may have been generated as a byproduct during the tetrazole ring synthesis step of the valsartan API. Furthermore, the detection of N-nitrosodiethylamine (NDEA) was subsequently announced by the EMA, FDA, and Health Canada.
The issue was not limited to valsartan; contamination was also confirmed in other sartan pharmaceuticals (Angiotensin II Receptor Blockers: ARBs), which are also antihypertensive agents, such as irbesartan and losartan, expanding the scope of recalls. One of the factors behind this was thought to be the adoption of similar manufacturing processes in these pharmaceuticals.
(3) Ongoing Recall Incidents
Since 2019, voluntary recalls related to nitrosamines have been reported domestically and internationally for the following pharmaceuticals:
-
Ranitidine hydrochloride (NDMA)
-
Nizatidine (NDMA)
-
Metformin hydrochloride (NDMA)
-
Mirabegron (N-nitrosomirabegron)
-
Entacapone (NDEA)
-
Cinacalcet hydrochloride (N-nitrosocinacalcet)
-
Atomoxetine hydrochloride (N-nitrosoatomoxetine)
These cases demonstrate that the nitrosamine issue is not limited to specific products, but is a challenge involving a wide range of factors, including pharmaceutical manufacturing processes, formulation design, and storage environments.
(4) Contamination Cases of Nitrosamine Drug Substance-Related Impurities (NDSRIs)
Initially, the nitrosamines that regulatory authorities focused on had relatively simple structures, such as NDMA and NDEA, but subsequently, numerous nitrosamines derived from the relevant drug substance (Nitrosamine Drug Substance-Related Impurities: NDSRIs) came to be reported. Unlike components specified by authorities (such as NDMA and NDEA), NDSRIs have diverse chemical structures derived from the API, making it necessary to establish analytical conditions for each individual component.
(5) Implementation of Self-Inspections Regarding the Risk of Nitrosamine Contamination in Pharmaceuticals
From September 2019 in Europe and September 2020 in the United States, regulatory authorities presented concepts for risk assessment and management regarding nitrosamines in pharmaceuticals, requiring marketing authorization holders and others to conduct contamination risk assessments.
In Japan, the notification “Self-Inspection on Risk of Nitrosamine Contamination in Pharmaceuticals” (Joint Notification of the Pharmaceutical Evaluation Division, Pharmaceutical Safety Division, and Compliance and Narcotics Division) was issued on October 8, 2021 (Reiwa 3), requiring pharmaceutical marketing authorization holders to evaluate nitrosamine contamination risks, measure actual values if contamination risks are identified, report cases exceeding limit values, and implement necessary risk mitigation measures.
However, in subsequent investigations, it became clear that conducting risk assessments and mitigation measures requires a considerable amount of time due to pointed-out possibilities of new contamination/formation routes and confirmed cases where identifying formation factors is difficult. In addition, practical constraints such as difficulties in obtaining reference standards for NDSRIs and shortages of resources like analytical instruments and analytical personnel were pointed out; in light of these circumstances, the deadline for implementing risk mitigation measures was extended from the initial October 31, 2024 (Reiwa 6) to August 1, 2025 (Reiwa 7).
2. Technical Challenges in the Operation of Nitrosamine Regulations
(1) Analytical Challenges Associated with Extremely Low Acceptable Intakes (AI)
In ICH-M7, the Threshold of Toxicological Concern (TTC) is applied to mutagenic impurities, typically setting an Acceptable Intake (AI) of $1.5\text{ }\mu\text{g/day}$ for lifetime exposure; however, because nitrosamines are classified in the Cohort of Concern, even lower AI values are set based on individual carcinogenicity data (e.g., NDEA $26\text{ ng/day}$, NDMA $96\text{ ng/day}$).
Furthermore, highly sensitive and selective analytical methods such as LC-MS/MS and GC-MS are required to comply with ng-level regulatory limits, demanding advanced technology and costs for daily maintenance and management; moreover, because pharmaceuticals have complex matrices that can cause false positives or false negatives, technical challenges exist in ensuring the specificity and robustness of analytical methods.
(2) Responding to Novel Nitrosamines (NDSRIs)
Because Nitrosamine Drug Substance-Related Impurities (NDSRIs) possess diverse chemical structures derived from the API, unlike components specified by authorities (such as NDMA and NDEA), establishing analytical conditions for each component is required.
On the other hand, many NDSRIs are novel compounds lacking animal carcinogenicity data, making it difficult to derive compound-specific AIs based on ICH-M7. Therefore, in silico toxicity assessments such as the Carcinogenic Potency Categorization Approach (CPCA), Structure-Activity Relationship (SAR), and read-across are utilized, though these predictions have certain limitations. In addition, commercially available reference standards do not exist for many NDSRIs, and synthesizing analytical reference standards often requires significant time and expense.
(3) Challenges in Applying Risk Assessments and Control Strategies
In ICH-M7, under the “Guideline on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk” (Notification No. 1110-3 of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, MHLW, dated November 10, 2015), risk assessment using purge factors (impurity removal efficiency at each step) in the manufacturing process is recognized as a control strategy for DNA-reactive impurities. However, because nitrosamines belong to the “Cohort of Concern” and may be formed or introduced in trace amounts throughout the entire manufacturing process, scientific proof that they are “reliably removed” (purging evaluation) is difficult, and in regulatory reviews, control through testing of the final product (Option 1) is often de facto required. Note that in Europe, it is stated that “if one or more N-nitrosamines are present at less than 10% of their respective AI, the toxicological risk is considered negligible and they do not need to be specified,” allowing omission from specifications, with the minimum quantifiable level being the Limit of Quantitation (LoQ).
According to the Self-Inspection Q&A, management without adding nitrosamine specification limits to the drug product specifications or applying skip testing for products where levels do not exceed the limit (below the limit but above the detection limit) is premised on a sufficient understanding of the root causes of nitrosamine contamination; since it cannot be judged possible solely based on measured nitrosamine values in the drug product falling below a certain percentage of the limit, responses equivalent to those for products exceeding the limit are essentially required.
(4) Excessive Management Burden
The AI for NDMA, one of the nitrosamines, is set extremely low at $96\text{ ng/day}$, requiring extremely strict management of formation factors in practice. Meanwhile, many APIs possess amino groups, and because various factors—such as starting materials, API manufacturing processes, formulation processes, packaging processes, and storage environments—can be involved in nitrosamine formation, completely eliminating the risk of formation is not easy, demanding wide-ranging management.
Under these circumstances, the following burdens are arising at manufacturing sites:
-
In high-sensitivity, specific analyses targeting the ppb (parts per billion) or lower range, maintaining the reproducibility of analytical instruments is difficult.
-
Analytical sample preparation is easily affected by trace contamination, requiring a high degree of skill from operators.
-
Even slight background differences can cause results to fluctuate, sometimes necessitating re-measurement.
-
Even if compliant with standards at the API stage, the final product may become non-compliant due to spontaneous formation during the formulation process or storage.
-
Additional tasks such as calculating acceptable limits (investigating existing information, utilizing CPCA, etc.), developing analytical methods, and investigating removal processes are increasing.
-
API manufacturers are also expending tremendous effort responding to inquiries regarding Master Files (MFs) and separate specifications.
Overall, the management burden on the ground is substantial in terms of both science/technology and operations, making compliance with regulatory requirements extremely burdensome.
(5) Challenges Specific to APIs
Even if compliant with standards at the API stage, the final product may become non-compliant due to spontaneous formation during the formulation process or storage; however, API manufacturers cannot directly manage the formation behavior of nitrosamines during the formulation process or drug product storage. Therefore, even when nitrosamines are confirmed during formulation or storage, the possibility that API manufacturers will be asked to review API manufacturing methods or change processes cannot be ruled out. To avoid such risks, strict management is sometimes essentially required at the API stage for amines that could serve as precursors, particularly secondary amines, suggesting the need to consider reasonable management levels that account for the process characteristics of both APIs and drug products.
Furthermore, even when a relatively systematic risk assessment is possible for the API manufacturing process, the fact that contamination by amines or nitrosating agents and their sources are often unclear for excipients and packaging materials used in drug products is another factor making risk assessment difficult. Meanwhile, obtaining the cooperation of all chemical manufacturers and others involved in pharmaceutical manufacturing is not easy in reality, placing limits on desktop risk assessments alone.
(6) Challenges in Regulatory Operations
Furthermore, the following cases have been raised by manufacturers and others as challenges in regulatory operations:
-
Although a control strategy was explained in advance based on purge factor calculations showing that residual mutagenic impurities in the API would be 1% of the acceptable limit, actual measurement results of the mutagenic impurity levels in the final API (or intermediate) were requested during MF inquiry responses.
-
When setting strict control values based on actual measured values is required, the operation deviates from the risk-based approach of ICH-M7, potentially placing a heavy burden on manufacturing sites.
-
Cases have been reported where the review period at the Pharmaceuticals and Medical Devices Agency (PMDA) takes more than two years from the initial inquiry to review completion, with scattered cases raising concerns over review delays.
-
When changing APIs, evaluations regarding the risk of nitrosamine formation or increase during the formulation process or storage may be required, complicating the review and sometimes hindering API changes. Additionally, due to the increased burden associated with partial change applications, some marketing authorization holders hesitate to submit applications even for changes aimed at ensuring stable supply.
There are concerns that review delays carry the risk of causing the following specific impacts:
-
Sharp decrease in market supply due to shipment holds
-
Chain-reaction supply instability caused by concentrated demand on other companies’ products
-
Difficulty in selecting alternative pharmaceuticals in clinical settings
-
Decreased motivation to submit change applications that contribute to stable supply, such as process improvements, manufacturing capacity increases, and adding API sources
(7) Specific Challenges at Manufacturing Sites
Examples where corporate member companies actually struggled to respond are described below.
| Category | Specific Challenges |
|---|---|
| Increase in workload due to excessive management |
|
| Lack of understanding of new guidelines |
|
| Chain reaction leading to insufficient development periods |
Originally, in risk assessments, both “nitrosamine contamination risk” and “stable supply risk” should be appropriately weighed and balanced to achieve an optimal equilibrium; it is essential to correctly evaluate contamination risks from a scientific perspective and establish reasonable control methods.
3. Recommendations of the Japanese Society of Generic and Biosimilar Medicines
Based on the current status and considerations regarding the management of nitrosamines described above, in order to continue ensuring the stable supply of safe pharmaceuticals—which is indispensable for maintaining and improving the healthy lives of the Japanese public—the Pharmaceutical Policy Subcommittee and the API Subcommittee of the Japanese Society of Generic and Biosimilar Medicines make the following recommendations regarding the management and operation of nitrosamines in pharmaceuticals and APIs.
Recommendations on the Management and Operation of Nitrosamines in APIs
The Japanese Society of Generic and Biosimilar Medicines: Pharmaceutical Policy Subcommittee & API Subcommittee
(Recommendation 1) Clarification of the scope of precursors subject to risk assessment
(Recommendation 2) Introduction of risk categories and establishment of tiered control levels according to category
(Recommendation 3) Introduction of reasonable controls based on appropriate testing
(Recommendation 4) Establishment of a management system across the entire supply chain, including APIs and drug products
(Recommendation 5) Ensuring stable pharmaceutical supply by strengthening the regulatory review system
(Recommendation 1) Clarification of the scope of precursors subject to risk assessment
In European and US guidance, secondary, tertiary, and quaternary amines are cited as examples of precursors for nitrosamine formation, but this scope is broad and vague, creating a practical need to conduct conservative assessments targeting almost all amines.
On the other hand, it is known that the risk of nitrosamine formation differs depending on molecular structure—for example, aromatic amines clearly have lower reactivity and are less susceptible to nitrosation compared to aliphatic amines.
Therefore, from the perspective of nitrosamine formation risk, we believe it is necessary to organize the target scope at the chemical structure level—such as:
-
Aliphatic amines
-
Aromatic amines
-
Nitrogen-containing heterocyclic compounds
—and for regulatory authorities to more clearly define the scope of precursors subject to evaluation, upon which risk-proportionate control strategies can be formulated.
(Recommendation 2) Introduction of risk categories and establishment of tiered control levels according to category
We propose comprehensively evaluating chemical structure, reactivity, known formation track records, usage amounts in drug products, etc., and based on this, establishing tiered risk categories proportionate to risk alongside control levels for each risk category.
Through this, it becomes possible to simultaneously achieve:
-
Focused management of high-risk substances
-
Reasonable simplification of management for low-risk substances
thereby reducing the burden of analysis and quality control to an appropriate level.
(Recommendation 3) Introduction of reasonable controls proportionate to formation risks during formulation processes and storage
It is known that nitrosamines may form or increase during formulation processes or storage. Therefore, we propose setting acceptable fluctuation allowances after considering acceptable limits and long-term stability test results, and introducing reasonable control strategies based on scientific evidence.
By introducing a management system that accounts for fluctuation margins during the shelf life, it becomes possible to design a rational institutional framework that ensures safety while preventing excessive recalls and supply halts.
(Recommendation 4) Establishment of a management system across the entire supply chain, including APIs and drug products
Factors contributing to nitrosamine formation—such as APIs, drug products, packaging, and storage—exist across the entire supply chain. Therefore, it is considered necessary to develop common industry-wide guidelines that include not only API manufacturers, but also:
-
Solvent manufacturers
-
Reagent manufacturers
-
Intermediate manufacturers
-
Packaging material manufacturers
Furthermore, it is desirable to establish a nationwide database (knowledge bank) for sharing information on nitrosamine formation factors and analytical know-how, utilizing it to prevent recurrence and build a rational regulatory framework.
(Recommendation 5) Ensuring stable pharmaceutical supply by strengthening the regulatory review system
Prolonged reviews for change applications and Master File changes accompanying nitrosamine responses have the potential to impact pharmaceutical supply.
Therefore, it is desirable to minimize the impact on the stable supply of pharmaceuticals by strengthening the review system and standardizing review periods through measures such as:
-
Increasing the number of specialized reviewers
-
Standardizing review periods
-
Clarifying technical judgment criteria
4. Conclusion
The nitrosamine issue is an important challenge directly linked to maintaining the social infrastructure of a stable pharmaceutical supply, in addition to ensuring medical safety. At manufacturing sites, numerous responses such as high-precision analyses and additional testing are required, and that burden is reaching a level close to its limit.
We hope that these recommendations will contribute to a rational review of institutional operations by regulatory authorities and related organizations, and lead to discussions toward realizing a system capable of continuously supplying safe and stable pharmaceuticals to the public in cooperation with European and US authorities.
The Japanese Society of Generic and Biosimilar Medicines intends to continue contributing to the compatibility of pharmaceutical quality assurance and stable supply through the accumulation of scientific knowledge and collaboration with related organizations.
The Japanese Society of Generic and Biosimilar Medicines Committee Roster
Pharmaceutical Policy Subcommittee
- Subcommittee Chair: Nobuya Koyama (Professor Emeritus, Toho University / Advisor, Japan Association of Private Medical Schools)
API Subcommittee
-
Subcommittee Chair: Masaki Muto (Director, Kinugasa Hospital Group, Japan Medical Missionary Society (Social Welfare Corporation) / Director, Yokosuka Community-Based Integrated Care Promotion Center)
-
Acting Subcommittee Chair: Hiroto Yoshiwaka (Representative & Pharmacist, A&G Pharma Consult LLC)
-
Members (in Japanese alphabetical order):
-
Ryuji Ikeda (Professor, Department of Pharmacy, University of Miyazaki Hospital)
-
Susumu Iwatsuki (President, Japan Pharmaceutical Association)
-
Kazumi Ota (Production Strategy Department, Production Division, Meiji Seika Pharma Co., Ltd.)
-
Ryotaro Katsura (Representative Director, Katsura Chemical Co., Ltd.)
-
Masahide Kawano (Laboratory of Regulatory Science, Graduate School of Meiji Pharmaceutical University)
-
Tomomi Kawamata (President and Representative Director, Nissin Pharmaceutical Co., Ltd.)
-
Satoshi Shiratori (President and Representative Director, Shiratori Pharmaceutical Co., Ltd.)
-
Katsunori Nakamura (Professor & Director of Pharmacy, University of the Ryukyus Hospital)
-
Kentaro Hayashi (Chairman, Barefoot Doctors Group)
-
Noriyuki Hayashi (A&G Pharma Consult LLC)
-
Osamu Hiruta (Visiting Professor, Faculty of Pharmaceutical Sciences, Tokyo University of Science / Graduate School of Pharmaceutical Sciences, Kumamoto University)
-
Ichiro Fujikawa (President and Representative Director, Fujikawa Co., Ltd.)
-
Kyoichi Yumoto (Senior Associate, Pharma Solutions Division, Sumitomo Chemical Co., Ltd.)
-
-
Secretariat:
-
Kenji Nishizawa (The Japanese Society of Generic and Biosimilar Medicines)
-
Shuhei Hosokawa (The Japanese Society of Generic and Biosimilar Medicines)
-